Related Experiment Video
Updated: Sep 13, 2025
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
4.0K
Lurasidone for Pediatric Bipolar Disorder: A Systematic Review
Alexia Koukopoulos1, Claudia Calderoni2,3, Georgios D Kotzalidis2,3
1Department of Life Science, Health and Health Professions, Link Campus University, 00165 Rome, Italy.
Pharmaceuticals (Basel, Switzerland)
|July 30, 2025
Summary
Lurasidone is an effective treatment for bipolar disorder in children and adolescents, showing positive results for manic and depressive symptoms with minimal side effects. This antipsychotic offers a safer alternative for pediatric patients.
Area of Science:
- Psychiatry and Behavioral Sciences
- Pediatric Mental Health
- Pharmacology
Background:
- Lurasidone, a second-generation antipsychotic, is approved for schizophrenia and mood disorders.
- Current treatments for pediatric bipolar disorder carry risks of weight gain and metabolic syndrome.
- Lurasidone's favorable side effect profile suggests potential as an alternative for young patients.
Purpose of the Study:
- To evaluate the efficacy and safety of lurasidone in children and adolescents with bipolar disorder.
- To synthesize existing evidence on lurasidone's use in pediatric populations with mood disorders.
Main Methods:
- Systematic review of literature using PubMed, CINAHL, PsycINFO, Scopus, and ClinicalTrials.gov.
- Search terms included 'lurasidone' and 'bipolar disorder' or related terms, filtered for humans aged 0-18.
- Eligibility criteria followed PRISMA-2020 guidelines, with consensus reached via Delphi rounds.
Main Results:
- The review included four case reports/series and six longitudinal studies involving 16,735 participants.
- Case reports showed mixed results, including one instance of mania induction.
- Longitudinal studies indicated generally good efficacy for both manic and depressive symptoms.
Conclusions:
- Lurasidone demonstrates favorable outcomes for pediatric bipolar disorder, addressing both manic and depressive symptoms.
- The medication appears to be well-tolerated, with no significant adverse side effects reported in this population.
- Lurasidone represents a promising therapeutic option for children and adolescents with bipolar disorder.
Related Concept Videos
01:24Mania and Antimanic Drugs: Overview
321
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
321
01:30Bipolar Disorder
144
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
144
01:28Drug Therapy
100
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
100
01:26Psychosis: Goals of Pharmacotherapy
209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
299
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
299
01:21Antipsychotic Drugs: Typical and Atypical Agents
320
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
320